Therapeutic implications of peptide interactions with G-protein-coupled receptors in diabetic vasculopathy

Acta Physiologica

Volumn 211, Issue 1, 2014, Pages 20-35

  Carrillo Sepulveda, M A ^a   Matsumoto, T ^b   Nunes, K P ^a,c   Webb, R C ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b HOSHI UNIVERSITY   (Japan)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Diabetic vascular complications; Endothelial cells; Peptide ligand; Vascular smooth muscle cells; Vasoconstriction; Vasodilatation

Indexed keywords

G PROTEIN COUPLED RECEPTOR; PEPTIDE;

DIABETIC ANGIOPATHIES; HUMAN; METABOLISM; VASCULAR ENDOTHELIUM;

DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; HUMANS; PEPTIDES; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84899067185     PISSN: 17481708     EISSN: 17481716     Source Type: Journal    
DOI: 10.1111/apha.12281     Document Type: Review

References (163)

1. Adams, M.N., Ramachandran, R., Yau, M.K., Suen, J.Y., Fairlie, D.P., Hollenberg, M.D. & Hooper, J.D. 2011. Structure, function and pathophysiology of protease activated receptors. Pharmacol Ther 130, 248-282.
2. Akhtar, S., Yousif, M.H., Dhaunsi, G.S., Chandrasekhar, B., Al-Farsi, O. & Benter, I.F. 2012. Angiotensin-(1-7) inhibits epidermal growth factor receptor transactivation via a Mas receptor-dependent pathway. Br J Pharmacol 165, 1390-1400.
3. Alexiadou, K., Kokkinos, A., Liatis, S., Perrea, D., Katsilambros, N. & Tentolouris, N. 2012. Differences in plasma apelin and visfatin levels between patients with type 1 diabetes mellitus and healthy subjects and response after acute hyperglycemia and insulin administration. Hormones (Athens) 11, 444-450.
4. Allahdadi, K.J., Hannan, J.L., Ergul, A., Tostes, R.C. & Webb, R.C. 2011. Internal pudendal artery from type 2 diabetic female rats demonstrate elevated endothelin-1-mediated constriction. J Sex Med 8, 2472-2483.
5. Ames, R.S., Sarau, H.M., Chambers, J.K., Willette, R.N., Aiyar, N.V., Romanic, A.M., Louden, C.S., Foley, J.J., Sauermelch, C.F., Coatney, R.W. et al. 1999. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401, 282-286.
6. Amini, P., Wadden, D., Cahill, F., Randell, E., Vasdev, S., Chen, X., Gulliver, W., Zhang, W., Zhang, H., Yi, Y. & Sun, G. 2012. Serum acylated ghrelin is negatively correlated with the insulin resistance in the CODING study. PLoS ONE 7, e45657.
7. Bader, M. & Ganten, D. 2008. Update on tissue renin-angiotensin systems. J Mol Med (Berl) 86, 615-621.
8. Bagi, Z., Feher, A., Cassuto, J., Akula, K., Labinskyy, N., Kaley, G. & Koller, A. 2011. Increased availability of angiotensin AT 1 receptors leads to sustained arterial constriction to angiotensin II in diabetes - role for Rho-kinase activation. Br J Pharmacol 163, 1059-1068.
9. Barry, G.D., Le, G.T. & Fairlie, D.P. 2006. Agonists and antagonists of protease activated receptors (PARs). Curr Med Chem 13, 243-265.
10. Bottrill, F.E., Douglas, S.A., Hiley, C.R. & White, R. 2000. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 130, 1865-1870.
11. Boucher, J., Masri, B., Daviaud, D., Gesta, S., Guigne, C., Mazzucotelli, A., Castan-Laurell, I., Tack, I., Knibiehler, B., Carpene, C., Audigier, Y., Saulnier-Blache, J.S. & Valet, P. 2005. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 146, 1764-1771.
12. Brenner, B.M., Cooper, M.E., de Zeeuw, D., Keane, W.F., Mitch, W.E., Parving, H.H., Remuzzi, G., Snapinn, S.M., Zhang, Z. & Shahinfar, S. 2001. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345, 861-869.
13. Brillante, D.G., O'Sullivan, A.J., Johnstone, M.T. & Howes, L.G. 2008. Evidence for functional expression of vascular angiotensin II type 2 receptors in patients with insulin resistance. Diabetes Obes Metab 10, 143-150.
14. Cai, H., Li, Z., Dikalov, S., Holland, S.M., Hwang, J., Jo, H., Dudley, S.C. Jr & Harrison, D.G. 2002. NAD(P)H oxidase-derived hydrogen peroxide mediates endothelial nitric oxide production in response to angiotensin II. J Biol Chem 277, 48311-48317.
15. Camarda, V., Rizzi, A., Calo, G., Gendron, G., Perron, S.I., Kostenis, E., Zamboni, P., Mascoli, F. & Regoli, D. 2002. Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn Schmiedebergs Arch Pharmacol 365, 141-149.
16. Camilleri, M. & Acosta, A. 2013. A ghrelin agonist fails to show benefit in patients with diabetic gastroparesis: let's not throw the baby out with the bath water. Neurogastroenterol Motil 25, 859-863.
17. Campbell, N.R., Gilbert, R.E., Leiter, L.A., Larochelle, P., Tobe, S., Chockalingam, A., Ward, R., Morris, D., Tsuyuki, R.T. & Harris, S.B. 2011. Hypertension in people with type 2 diabetes: update on pharmacologic management. Can Fam Physician 57, 997-1002, e347-53.
18. Cardillo, C., Campia, U., Bryant, M.B. & Panza, J.A. 2002. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 106, 1783-1787.
19. Carreira, M.C., Camina, J.P., Smith, R.G. & Casanueva, F.F. 2004. Agonist-specific coupling of growth hormone secretagogue receptor type 1a to different intracellular signaling systems. Role of adenosine. Neuroendocrinology 79, 13-25.
20. Castan-Laurell, I., Boucher, J., Dray, C., Daviaud, D., Guigne, C. & Valet, P. 2005. Apelin, a novel adipokine over-produced in obesity: friend or foe? Mol Cell Endocrinol 245, 7-9.
21. Castan-Laurell, I., Dray, C., Attane, C., Duparc, T., Knauf, C. & Valet, P. 2011. Apelin, diabetes, and obesity. Endocrine 40, 1-9.
22. Cavallo, M.G., Sentinelli, F., Barchetta, I., Costantino, C., Incani, M., Perra, L., Capoccia, D., Romeo, S., Cossu, E., Leonetti, F., Agati, L. & Baroni, M.G. 2012. Altered glucose homeostasis is associated with increased serum apelin levels in type 2 diabetes mellitus. PLoS ONE 7, e51236.
23. Celi, F., Bini, V., Papi, F., Santilli, E., Ferretti, A., Mencacci, M., Berioli, M.G., De Giorgi, G. & Falorni, A. 2005. Circulating acylated and total ghrelin and galanin in children with insulin-treated type 1 diabetes: relationship to insulin therapy, metabolic control and pubertal development. Clin Endocrinol (Oxf) 63, 139-145.
24. Chappell, M.C. 2007. Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure? Hypertension 50, 596-599.
25. Chen, H., Li, J., Jiao, L., Petersen, R.B., Peng, A., Zheng, L. & Huang, K. 2014. Apelin inhibits the development of diabetic nephropathy by regulating histone acetylation in Akita mouse. J Physiol 592, 505-521.
26. Chu, K.Y. & Leung, P.S. 2009. Angiotensin II in type 2 diabetes mellitus. Curr Protein Pept Sci 10, 75-84.
27. Dai, D.Z. & Dai, Y. 2010. Role of endothelin receptor A and NADPH oxidase in vascular abnormalities. Vasc Health Risk Manag 6, 787-794.
28. D'Andrea, M.R., Derian, C.K., Leturcq, D., Baker, S.M., Brunmark, A., Ling, P., Darrow, A.L., Santulli, R.J., Brass, L.F. & Andrade-Gordon, P. 1998. Characterization of protease-activated receptor-2 immunoreactivity in normal human tissues. J Histochem Cytochem 46, 157-164.
29. Date, Y., Kojima, M., Hosoda, H., Sawaguchi, A., Mondal, M.S., Suganuma, T., Matsukura, S., Kangawa, K. & Nakazato, M. 2000. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141, 4255-4261.
30. Day, R.T., Cavaglieri, R.C. & Feliers, D. 2013. Apelin retards the progression of diabetic nephropathy. Am J Physiol Renal Physiol 304, F788-F800.
31. Douglas, S.A., Sulpizio, A.C., Piercy, V., Sarau, H.M., Ames, R.S., Aiyar, N.V., Ohlstein, E.H. & Willette, R.N. 2000. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 131, 1262-1274.
32. Echeverria-Rodriguez, O., Del Valle-Mondragon, L. & Hong, E. 2013. Angiotensin 1-7 improves insulin sensitivity by increasing skeletal muscle glucose uptake in vivo. Peptides 51C, 26-30.
33. Erdem, G., Dogru, T., Tasci, I., Sonmez, A. & Tapan, S. 2008. Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 116, 289-292.
34. Ergul, A. 2011. Endothelin-1 and diabetic complications: focus on the vasculature. Pharmacol Res 63, 477-482.
35. Fang, H., Hong, Z., Zhang, J., Shen, D.F., Gao, F.F., Sugiyama, K., Namba, H. & Asakawa, T. 2012. Effects of ghrelin on the intracellular calcium concentration in rat aorta vascular smooth muscle cells. Cell Physiol Biochem 30, 1299-1309.
36. Fraga-Silva, R.A., Costa-Fraga, F.P., Murca, T.M., Moraes, P.L., Martins Lima, A., Lautner, R.Q., Castro, C.H., Soares, C.M., Borges, C.L., Nadu, A.P. et al. 2013. Angiotensin-converting enzyme 2 activation improves endothelial function. Hypertension 61, 1233-1238.
37. Fujita, H., Sakamoto, T., Komatsu, K., Fujishima, H., Morii, T., Narita, T., Takahashi, T. & Yamada, Y. 2011. Reduction of circulating superoxide dismutase activity in type 2 diabetic patients with microalbuminuria and its modulation by telmisartan therapy. Hypertens Res 34, 1302-1308.
38. Galanth, C., Hus-Citharel, A., Li, B. & Llorens-Cortes, C. 2012. Apelin in the control of body fluid homeostasis and cardiovascular functions. Curr Pharm Des 18, 789-798.
39. Gardiner, S.M., March, J.E., Kemp, P.A., Maguire, J.J., Kuc, R.E., Davenport, A.P. & Bennett, T. 2006. Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation. Br J Pharmacol 147, 612-621.
40. Gauna, C., Delhanty, P.J., Hofland, L.J., Janssen, J.A., Broglio, F., Ross, R.J., Ghigo, E. & van der Lely, A.J. 2005. Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. J Clin Endocrinol Metab 90, 1055-1060.
41. Gibson, A. 1987. Complex effects of Gillichthys urotensin II on rat aortic strips. Br J Pharmacol 91, 205-212.
42. Gnanapavan, S., Kola, B., Bustin, S.A., Morris, D.G., McGee, P., Fairclough, P., Bhattacharya, S., Carpenter, R., Grossman, A.B. & Korbonits, M. 2002. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 87, 2988.
43. Gray, G.A., Jones, M.R. & Sharif, I. 2001. Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition. Life Sci 69, 175-180.
44. Grisk, O. 2007. Apelin and vascular dysfunction in type 2 diabetes. Cardiovasc Res 74, 339-340.
45. Gruson, D., Rousseau, M.F., Ketelslegers, J.M. & Hermans, M.P. 2010. Raised plasma urotensin II in type 2 diabetes patients is associated with the metabolic syndrome phenotype. J Clin Hypertens (Greenwich) 12, 653-660.
46. Gualillo, O., Lago, F., Gomez-Reino, J., Casanueva, F.F. & Dieguez, C. 2003. Ghrelin, a widespread hormone: insights into molecular and cellular regulation of its expression and mechanism of action. FEBS Lett 552, 105-109.
47. Hamilton, J.R., Frauman, A.G. & Cocks, T.M. 2001. Increased expression of protease-activated receptor-2 (PAR2) and PAR4 in human coronary artery by inflammatory stimuli unveils endothelium-dependent relaxations to PAR2 and PAR4 agonists. Circ Res 89, 92-98.
48. Hirata, A.E., Morgan, D., Oliveira-Emilio, H.R., Rocha, M.S., Carvalho, C.R., Curi, R. & Carpinelli, A.R. 2009. Angiotensin II induces superoxide generation via NAD(P)H oxidase activation in isolated rat pancreatic islets. Regul Pept 153, 1-6.
49. Howard, A.D., Feighner, S.D., Cully, D.F., Arena, J.P., Liberator, P.A., Rosenblum, C.I., Hamelin, M., Hreniuk, D.L., Palyha, O.C., Anderson, J. et al. 1996. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273, 974-977.
50. Iglewski, M. & Grant, S.R. 2010. Urotensin II-induced signaling involved in proliferation of vascular smooth muscle cells. Vasc Health Risk Manag 6, 723-734.
51. Ishida, K., Matsumoto, T., Taguchi, K., Kamata, K. & Kobayashi, T. 2012. Pravastatin normalizes endothelium-derived contracting factor-mediated response via suppression of Rho-kinase signalling in mesenteric artery from aged type 2 diabetic rat. Acta Physiol (Oxf) 205, 255-265.
52. Ishida, K., Matsumoto, T., Taguchi, K., Kamata, K. & Kobayashi, T. 2013. Mechanisms underlying reduced P2Y(1) -receptor-mediated relaxation in superior mesenteric arteries from long-term streptozotocin-induced diabetic rats. Acta Physiol (Oxf) 207, 130-141.
53. Ishihata, A., Ogaki, T., Aita, T. & Katano, Y. 2005. Role of prostaglandins in urotensin II-induced vasodilatation in the coronary arteries of aged rats. Eur J Pharmacol 523, 119-126.
54. Iturrioz, X., Alvear-Perez, R., De Mota, N., Franchet, C., Guillier, F., Leroux, V., Dabire, H., Le Jouan, M., Chabane, H., Gerbier, R. et al. 2010. Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist. FASEB J 24, 1506-1517.
55. Jin, H.M. & Pan, Y. 2007. Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. Nephrol Dial Transplant 22, 1943-1949.
56. Jones, E.S., Vinh, A., McCarthy, C.A., Gaspari, T.A. & Widdop, R.E. 2008. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther 120, 292-316.
57. Kagota, S., Chia, E. & McGuire, J.J. 2011. Preserved arterial vasodilatation via endothelial protease-activated receptor-2 in obese type 2 diabetic mice. Br J Pharmacol 164, 358-371.
58. Kamata, K., Kanie, N., Matsumoto, T. & Kobayashi, T. 2004. Endothelin-1-induced impairment of endothelium-dependent relaxation in aortas isolated from controls and diabetic rats. J Cardiovasc Pharmacol 44(Suppl 1), S186-S190.
59. Katano, Y., Ishihata, A., Aita, T., Ogaki, T. & Horie, T. 2000. Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries. Eur J Pharmacol 402, R5-R7.
60. Katugampola, S.D., Maguire, J.J., Matthewson, S.R. & Davenport, A.P. 2001. [(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol 132, 1255-1260.
61. Kawamata, Y., Habata, Y., Fukusumi, S., Hosoya, M., Fujii, R., Hinuma, S., Nishizawa, N., Kitada, C., Onda, H., Nishimura, O. & Fujino, M. 2001. Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta 1538, 162-171.
62. Kelly-Cobbs, A.I., Harris, A.K., Elgebaly, M.M., Li, W., Sachidanandam, K., Portik-Dobos, V., Johnson, M. & Ergul, A. 2011. Endothelial endothelin B receptor-mediated prevention of cerebrovascular remodeling is attenuated in diabetes because of up-regulation of smooth muscle endothelin receptors. J Pharmacol Exp Ther 337, 9-15.
63. Kirchner, H., Gutierrez, J.A., Solenberg, P.J., Pfluger, P.T., Czyzyk, T.A., Willency, J.A., Schurmann, A., Joost, H.G., Jandacek, R.J., Hale, J.E., Heiman, M.L. & Tschop, M.H. 2009. GOAT links dietary lipids with the endocrine control of energy balance. Nat Med 15, 741-745.
64. Kleinz, M.J. & Davenport, A.P. 2004. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept 118, 119-125.
65. Kleinz, M.J. & Davenport, A.P. 2005. Emerging roles of apelin in biology and medicine. Pharmacol Ther 107, 198-211.
66. Kleinz, M.J., Maguire, J.J., Skepper, J.N. & Davenport, A.P. 2006. Functional and immunocytochemical evidence for a role of ghrelin and des-octanoyl ghrelin in the regulation of vascular tone in man. Cardiovasc Res 69, 227-235.
67. Kobayashi, T., Nogami, T., Taguchi, K., Matsumoto, T. & Kamata, K. 2008. Diabetic state, high plasma insulin and angiotensin II combine to augment endothelin-1-induced vasoconstriction via ETA receptors and ERK. Br J Pharmacol 155, 974-983.
68. Kohan, D.E., Pritchett, Y., Molitch, M., Wen, S., Garimella, T., Audhya, P. & Andress, D.L. 2011. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 22, 763-772.
69. Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H. & Kangawa, K. 1999. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656-660.
70. Lago, R.M., Singh, P.P. & Nesto, R.W. 2007. Diabetes and hypertension. Nat Clin Pract Endocrinol Metab 3, 667.
71. Lam, H.C., Lee, J.K., Lu, C.C., Chu, C.H., Chuang, M.J. & Wang, M.C. 2003. Role of endothelin in diabetic retinopathy. Curr Vasc Pharmacol 1, 243-250.
72. Leehey, D.J., Singh, A.K., Alavi, N. & Singh, R. 2000. Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 77, S93-S98.
73. Lewis, E.J., Hunsicker, L.G., Clarke, W.R., Berl, T., Pohl, M.A., Lewis, J.B., Ritz, E., Atkins, R.C., Rohde, R. & Raz, I. 2001. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345, 851-860.
74. Li, L., Xie, F., Zhang, Z., Guo, Y., Tang, G., Lv, D., Lu, Q., Chen, L. & Li, J. 2013. Jagged-1/Notch3 signaling transduction pathway is involved in apelin-13-induced vascular smooth muscle cells proliferation. Acta Biochim Biophys Sin (Shanghai) 45, 875-881.
75. Liu, Q., Pong, S.S., Zeng, Z., Zhang, Q., Howard, A.D., Williams, D.L. Jr, Davidoff, M., Wang, R., Austin, C.P., McDonald, T.P., Bai, C., George, S.R., Evans, J.F. & Caskey, C.T. 1999. Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun 266, 174-178.
76. Llorens, S., Miranda, F.J., Alabadi, J.A., Marrachelli, V.G. & Alborch, E. 2004. Different role of endothelin ETA and ETB receptors and endothelial modulators in diabetes-induced hyperreactivity of the rabbit carotid artery to endothelin-1. Eur J Pharmacol 486, 43-51.
77. Lu, Q., Feng, J. & Jiang, Y.R. 2013. The role of apelin in the retina of diabetic rats. PLoS ONE 8, e69703.
78. MacLean, M.R., Alexander, D., Stirrat, A., Gallagher, M., Douglas, S.A., Ohlstein, E.H., Morecroft, I. & Polland, K. 2000. Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 130, 201-204.
79. Makino, A. & Kamata, K. 2000. Time-course changes in plasma endothelin-1 and its effects on the mesenteric arterial bed in streptozotocin-induced diabetic rats. Diabetes Obes Metab 2, 47-55.
80. Mann, J.F., Green, D., Jamerson, K., Ruilope, L.M., Kuranoff, S.J., Littke, T. & Viberti, G. 2010. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 21, 527-535.
81. Matsumoto, T., Kobayashi, T. & Kamata, K. 2008. Relationships among ET-1, PPARgamma, oxidative stress and endothelial dysfunction in diabetic animals. J Smooth Muscle Res 44, 41-55.
82. Matsumoto, T., Ishida, K., Nakayama, N., Kobayashi, T. & Kamata, K. 2009a. Involvement of NO and MEK/ERK pathway in enhancement of endothelin-1-induced mesenteric artery contraction in later-stage type 2 diabetic Goto-Kakizaki rat. Am J Physiol Heart Circ Physiol 296, H1388-H1397.
83. Matsumoto, T., Ishida, K., Taguchi, K., Kobayashi, T. & Kamata, K. 2009b. Mechanisms underlying enhanced vasorelaxant response to protease-activated receptor 2-activating peptide in type 2 diabetic Goto-Kakizaki rat mesenteric artery. Peptides 30, 1729-1734.
84. Matsumoto, T., Ishida, K., Nakayama, N., Taguchi, K., Kobayashi, T. & Kamata, K. 2010a. Mechanisms underlying the losartan treatment-induced improvement in the endothelial dysfunction seen in mesenteric arteries from type 2 diabetic rats. Pharmacol Res 62, 271-281.
85. Matsumoto, T., Ishida, K., Taguchi, K., Kobayashi, T. & Kamata, K. 2010b. Short-term angiotensin-1 receptor antagonism in type 2 diabetic Goto-Kakizaki rats normalizes endothelin-1-induced mesenteric artery contraction. Peptides 31, 609-617.
86. McCallum, R.W., Lembo, A., Esfandyari, T., Bhandari, B.R., Ejskjaer, N., Cosentino, C., Helton, N., Mondou, E., Quinn, J. & Rousseau, F. 2013. Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil 25, e705-e717.
87. Meral, C., Tascilar, E., Karademir, F., Tanju, I.A., Cekmez, F., Ipcioglu, O.M., Ercin, C.N., Gocmen, I. & Dogru, T. 2010. Elevated plasma levels of apelin in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 23, 497-502.
88. Michel, M.C., Foster, C., Brunner, H.R. & Liu, L. 2013. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev 65, 809-848.
89. Molino, M., Raghunath, P.N., Kuo, A., Ahuja, M., Hoxie, J.A., Brass, L.F. & Barnathan, E.S. 1998. Differential expression of functional protease-activated receptor-2 (PAR-2) in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 18, 825-832.
90. Moller, N., Nygren, J., Hansen, T.K., ØRskov, H., Frystyk, J. & Nair, K.S. 2003. Splanchnic release of ghrelin in humans. J Clin Endocrinol Metab 88, 850-852.
91. Muniyappa, R. & Sowers, J.R. 2013. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord 14, 5-12.
92. Muniyappa, R. & Yavuz, S. 2013. Metabolic actions of angiotensin II and insulin: a microvascular endothelial balancing act. Mol Cell Endocrinol 378, 59-69.
93. Murdolo, G., Lucidi, P., Di Loreto, C., Parlanti, N., De Cicco, A., Fatone, C., Fanelli, C.G., Bolli, G.B., Santeusanio, F. & De Feo, P. 2003. Insulin is required for prandial ghrelin suppression in humans. Diabetes 52, 2923-2927.
94. Nakamura, S., Tsuruma, K., Shimazawa, M. & Hara, H. 2012. Candesartan, an angiotensin II type 1 receptor antagonist, inhibits pathological retinal neovascularization by downregulating VEGF receptor-2 expression. Eur J Pharmacol 685, 8-14.
95. Nguyen Dinh Cat, A. & Touyz, R.M. 2011. A new look at the renin-angiotensin system-focusing on the vascular system. Peptides 32, 2141-2150.
96. Nickenig, G. & Bohm, M. 1998. Interaction between insulin and AT1 receptor. Relevance for hypertension and arteriosclerosis. Basic Res Cardiol 93(Suppl 2), 135-139.
97. Nickenig, G., Roling, J., Strehlow, K., Schnabel, P. & Bohm, M. 1998. Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. Circulation 98, 2453-2460.
98. Nicola, W., Sidhom, G., El Khyat, Z., Ibrahim, S., Salah, A. & El Sayed, A. 2001. Plasma angiotensin II, renin activity and serum angiotensin-converting enzyme activity in non-insulin dependent diabetes mellitus patients with diabetic nephropathy. Endocr J 48, 25-31.
99. Northrup, R., Kuroda, K., Duus, E.M., Barnes, S.R., Cheatham, L., Wiley, T. & Pietra, C. 2013. Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model. Support Care Cancer 21, 2409-2415.
100. Nothacker, H.P., Wang, Z., McNeill, A.M., Saito, Y., Merten, S., O'Dowd, B., Duckles, S.P. & Civelli, O. 1999. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol 1, 383-385.
101. Nunes, K.P., Rigsby, C.S. & Webb, R.C. 2010. RhoA/Rho-kinase and vascular diseases: what is the link? Cell Mol Life Sci 67, 3823-3836.
102. O'Dowd, B.F., Heiber, M., Chan, A., Heng, H.H., Tsui, L.C., Kennedy, J.L., Shi, X., Petronis, A., George, S.R. & Nguyen, T. 1993. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 136, 355-360.
103. Ossovskaya, V.S. & Bunnett, N.W. 2004. Protease-activated receptors: contribution to physiology and disease. Physiol Rev 84, 579-621.
104. Park, Y., Yang, J., Zhang, H., Chen, X. & Zhang, C. 2011. Effect of PAR2 in regulating TNF-alpha and NAD(P)H oxidase in coronary arterioles in type 2 diabetic mice. Basic Res Cardiol 106, 111-123.
105. Parthier, C., Reedtz-Runge, S., Rudolph, R. & Stubbs, M.T. 2009. Passing the baton in class B GPCRs: peptide hormone activation via helix induction? Trends Biochem Sci 34, 303-310.
106. Patacchini, R., Santicioli, P., Giuliani, S., Grieco, P., Novellino, E., Rovero, P. & Maggi, C.A. 2003. Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta. Br J Pharmacol 140, 1155-1158.
107. Pearson, D., Shively, J.E., Clark, B.R., Geschwind, I.I., Barkley, M., Nishioka, R.S. & Bern, H.A. 1980. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci USA 77, 5021-5024.
108. Pernow, J., Shemyakin, A. & Bohm, F. 2012. New perspectives on endothelin-1 in atherosclerosis and diabetes mellitus. Life Sci 91, 507-516.
109. Pong, S.S., Chaung, L.Y., Dean, D.C., Nargund, R.P., Patchett, A.A. & Smith, R.G. 1996. Identification of a new G-protein-linked receptor for growth hormone secretagogues. Mol Endocrinol 10, 57-61.
110. Poykko, S.M., Kellokoski, E., Horkko, S., Kauma, H., Kesaniemi, Y.A. & Ukkola, O. 2003. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 52, 2546-2553.
111. Rehman, A., Leibowitz, A., Yamamoto, N., Rautureau, Y., Paradis, P. & Schiffrin, E.L. 2012. Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 59, 291-299.
112. Rodriguez-Moyano, M., Diaz, I., Dionisio, N., Zhang, X., Avila-Medina, J., Calderon-Sanchez, E., Trebak, M., Rosado, J.A., Ordonez, A. & Smani, T. 2013. Urotensin-II promotes vascular smooth muscle cell proliferation through store-operated calcium entry and EGFR transactivation. Cardiovasc Res 100, 297-306.
113. Ross, B., McKendy, K. & Giaid, A. 2010. Role of urotensin II in health and disease. Am J Physiol Regul Integr Comp Physiol 298, R1156-R1172.
114. Rossing, K., Christensen, P.K., Hansen, B.V., Carstensen, B. & Parving, H.H. 2003. Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study. Diabetes Care 26, 150-155.
115. Rossowski, W.J., Cheng, B.L., Taylor, J.E., Datta, R. & Coy, D.H. 2002. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. Eur J Pharmacol 438, 159-170.
116. Roviezzo, F., Bucci, M., Brancaleone, V., Di Lorenzo, A., Geppetti, P., Farneti, S., Parente, L., Lungarella, G., Fiorucci, S. & Cirino, G. 2005. Proteinase-activated receptor-2 mediates arterial vasodilation in diabetes. Arterioscler Thromb Vasc Biol 25, 2349-2354.
117. Sabuhi, R., Ali, Q., Asghar, M., Al-Zamily, N.R. & Hussain, T. 2011. Role of the angiotensin II AT2 receptor in inflammation and oxidative stress: opposing effects in lean and obese Zucker rats. Am J Physiol Renal Physiol 300, F700-F706.
118. Sachidanandam, K., Portik-Dobos, V., Harris, A.K., Hutchinson, J.R., Muller, E., Johnson, M.H. & Ergul, A. 2007. Evidence for vasculoprotective effects of ETB receptors in resistance artery remodeling in diabetes. Diabetes 56, 2753-2758.
119. Sachidanandam, K., Portik-Dobos, V., Kelly-Cobbs, A.I. & Ergul, A. 2010. Dual endothelin receptor antagonism prevents remodeling of resistance arteries in diabetes. Can J Physiol Pharmacol 88, 616-621.
120. Sakurai, T., Yanagisawa, M., Takuwa, Y., Miyazaki, H., Kimura, S., Goto, K. & Masaki, T. 1990. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348, 732-735.
121. Sankararamakrishnan, R. 2006. Recognition of GPCRs by peptide ligands and membrane compartments theory: structural studies of endogenous peptide hormones in membrane environment. Biosci Rep 26, 131-158.
122. Sarafidis, P.A. & Lasaridis, A.N. 2010. Diabetic nephropathy: endothelin antagonism for diabetic nephropathy. Nat Rev Nephrol 6, 447-449.
123. Sato-Horiguchi, C., Ogawa, D., Wada, J., Tachibana, H., Kodera, R., Eguchi, J., Nakatsuka, A., Terami, N., Shikata, K. & Makino, H. 2013. Telmisartan attenuates diabetic nephropathy by suppressing oxidative stress in db/db mice. Nephron Exp Nephrol 121, e97-e108.
124. Scheen, A.J. 2004. Prevention of type 2 diabetes mellitus through inhibition of the Renin-angiotensin system. Drugs 64, 2537-2565.
125. Sen, S., Chen, S., Feng, B., Iglarz, M. & Chakrabarti, S. 2012. Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist. Life Sci 91, 658-668.
126. Shao, Y., He, M., Zhou, L., Yao, T., Huang, Y. & Lu, L.M. 2008. Chronic angiotensin (1-7) injection accelerates STZ-induced diabetic renal injury. Acta Pharmacol Sin 29, 829-837.
127. Shimizu, Y., Nagaya, N., Isobe, T., Imazu, M., Okumura, H., Hosoda, H., Kojima, M., Kangawa, K. & Kohno, N. 2003. Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res 9, 774-778.
128. Sidharta, P.N., Wagner, F.D., Bohnemeier, H., Jungnik, A., Halabi, A., Krahenbuhl, S., Chadha-Boreham, H. & Dingemanse, J. 2006. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther 80, 246-256.
129. Singh, K., Sharma, K., Singh, M. & Sharma, P.L. 2012. Possible mechanism of the cardio-renal protective effects of AVE-0991, a non-peptide Mas-receptor agonist, in diabetic rats. J Renin Angiotensin Aldosterone Syst 13, 334-340.
130. Sodhi, C.P., Kanwar, Y.S. & Sahai, A. 2003. Hypoxia and high glucose upregulate AT1 receptor expression and potentiate ANG II-induced proliferation in VSM cells. Am J Physiol Heart Circ Physiol 284, H846-H852.
131. Sondermeijer, B., Kompa, A., Komesaroff, P. & Krum, H. 2005. Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension. Am J Hypertens 18, 1195-1199.
132. Soriguer, F., Garrido-Sanchez, L., Garcia-Serrano, S., Garcia-Almeida, J.M., Garcia-Arnes, J., Tinahones, F.J. & Garcia-Fuentes, E. 2009. Apelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus. Obes Surg 19, 1574-1580.
133. Steckelings, U.M., Paulis, L., Namsolleck, P. & Unger, T. 2012. AT2 receptor agonists: hypertension and beyond. Curr Opin Nephrol Hypertens 21, 142-146.
134. Suguro, T., Watanabe, T., Kodate, S., Xu, G., Hirano, T., Adachi, M. & Miyazaki, A. 2008. Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes. Clin Sci (Lond) 115, 327-334.
135. Sumi, A., Yamanaka-Hanada, N., Bai, F., Makino, T., Mizukami, H. & Ono, T. 2011. Roles of coagulation pathway and factor Xa in the progression of diabetic nephropathy in db/db mice. Biol Pharm Bull 34, 824-830.
136. Taguchi, K., Matsumoto, T., Kamata, K. & Kobayashi, T. 2013. Suppressed G-protein-coupled receptor kinase 2 activity protects female diabetic-mouse aorta against endothelial dysfunction. Acta Physiol (Oxf) 207, 142-155.
137. Tallant, E.A., Diz, D.I. & Ferrario, C.M. 1999. State-of-the-Art lecture. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle. Hypertension 34, 950-957.
138. Tao, Y., Lu, Q., Jiang, Y.R., Qian, J., Wang, J.Y., Gao, L. & Jonas, J.B. 2010. Apelin in plasma and vitreous and in fibrovascular retinal membranes of patients with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 51, 4237-4242.
139. Tatemoto, K., Hosoya, M., Habata, Y., Fujii, R., Kakegawa, T., Zou, M.X., Kawamata, Y., Fukusumi, S., Hinuma, S., Kitada, C., Kurokawa, T., Onda, H. & Fujino, M. 1998. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 251, 471-476.
140. Tesauro, M., Schinzari, F., Iantorno, M., Rizza, S., Melina, D., Lauro, D. & Cardillo, C. 2005. Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation 112, 2986-2992.
141. Totsune, K., Takahashi, K., Arihara, Z., Sone, M., Murakami, O., Ito, S., Kikuya, M., Ohkubo, T., Hashimoto, J. & Imai, Y. 2004. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 25, 1809-1814.
142. Toyama, K., Nakamura, T., Kataoka, K., Yasuda, O., Fukuda, M., Tokutomi, Y., Dong, Y.F., Ogawa, H. & Kim-Mitsuyama, S. 2011. Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-gamma-dependent activity. Biochem Biophys Res Commun 410, 508-513.
143. Tsai, C.S., Loh, S.H., Liu, J.C., Lin, J.W., Chen, Y.L., Chen, C.H. & Cheng, T.H. 2009. Urotensin II-induced endothelin-1 expression and cell proliferation via epidermal growth factor receptor transactivation in rat aortic smooth muscle cells. Atherosclerosis 206, 86-94.
144. Urwyler, S. 2011. Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives. Pharmacol Rev 63, 59-126.
145. Vogt, L., Chiurchiu, C., Chadha-Boreham, H., Danaietash, P., Dingemanse, J., Hadjadj, S., Krum, H., Navis, G., Neuhart, E., Parvanova, A.I., Ruggenenti, P., Woittiez, A.J., Zimlichman, R., Remuzzi, G. & de Zeeuw, D. 2010. Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy. Hypertension 55, 1206-1209.
146. Wang, H.X., Zeng, X.J., Liu, Y., Wang, J., Lu, L.Q., Hao, G., Zhang, L.K. & Tang, C.S. 2009. Elevated expression of urotensin II and its receptor in skeletal muscle of diabetic mouse. Regul Pept 154, 85-90.
147. Wassmann, S. & Nickenig, G. 2006. Pathophysiological regulation of the AT1-receptor and implications for vascular disease. J Hypertens Suppl 24, S15-S21.
148. Watanabe, T., Kanome, T., Miyazaki, A. & Katagiri, T. 2006. Human urotensin II as a link between hypertension and coronary artery disease. Hypertens Res 29, 375-387.
149. Watson, A.M., Olukman, M., Koulis, C., Tu, Y., Samijono, D., Yuen, D., Lee, C., Behm, D.J., Cooper, M.E., Jandeleit-Dahm, K.A., Calkin, A.C. & Allen, T.J. 2013. Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes. Diabetologia 56, 1155-1165.
150. Wesselman, J.P. & De Mey, J.G. 2002. Angiotensin and cytoskeletal proteins: role in vascular remodeling. Curr Hypertens Rep 4, 63-70.
151. White, H.K., Petrie, C.D., Landschulz, W., MacLean, D., Taylor, A., Lyles, K., Wei, J.Y., Hoffman, A.R., Salvatori, R., Ettinger, M.P., Morey, M.C., Blackman, M.R. & Merriam, G.R. 2009. Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab 94, 1198-1206.
152. Williams, B., Baker, A.Q., Gallacher, B. & Lodwick, D. 1995. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 25, 913-917.
153. Wolf, G. & Ritz, E. 2005. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 67, 799-812.
154. Xiang, Y., Li, Q., Li, M., Wang, W., Cui, C. & Zhang, J. 2011. Ghrelin inhibits AGEs-induced apoptosis in human endothelial cells involving ERK1/2 and PI3K/Akt pathways. Cell Biochem Funct 29, 149-155.
155. Xie, N. & Liu, L. 2009. Elevated expression of urotensin II and its receptor in great artery of type 2 diabetes and its significance. Biomed Pharmacother 63, 734-741.
156. Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K. & Masaki, T. 1988. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332, 411-415.
157. Yang, J., Brown, M.S., Liang, G., Grishin, N.V. & Goldstein, J.L. 2008. Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 132, 387-396.
158. Yoshimoto, T., Matsushita, M. & Hirata, Y. 2004. Role of urotensin II in peripheral tissue as an autocrine/paracrine growth factor. Peptides 25, 1775-1781.
159. Yue, P., Jin, H., Aillaud, M., Deng, A.C., Azuma, J., Asagami, T., Kundu, R.K., Reaven, G.M., Quertermous, T. & Tsao, P.S. 2010. Apelin is necessary for the maintenance of insulin sensitivity. Am J Physiol Endocrinol Metab 298, E59-E67.
160. Zhang, B.H., Wang, W., Wang, H., Yin, J. & Zeng, X.J. 2013. Promoting effects of the adipokine, apelin, on diabetic nephropathy. PLoS ONE 8, e60457.
161. Zhong, J.C., Yu, X.Y., Huang, Y., Yung, L.M., Lau, C.W. & Lin, S.G. 2007. Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice. Cardiovasc Res 74, 388-395.
162. Zhou, Y.B., Gao, Q., Li, P., Han, Y., Zhang, F., Qi, Y.F., Tang, C.S., Gao, X.Y. & Zhu, G.Q. 2013. Adrenomedullin attenuates vascular calcification in fructose-induced insulin resistance rats. Acta Physiol (Oxf) 207, 437-446.
163. Zomer, E., de Ridder, I., Kompa, A., Komesaroff, P., Gilbert, R. & Krum, H. 2008. Effect of urotensin II on skin microvessel tone in diabetic patients without heart failure or essential hypertension. Clin Exp Pharmacol Physiol 35, 1147-1150.